Rapport Therapeutics, Inc. (RAPP) Stock Price & How to Invest

Rapport Therapeutics (Nasdaq: RAPP) is a clinical-stage biotechnology company building small-molecule precision medicines for neurological and psychiatric conditions. Its platform is based on receptor associated proteins (RAPs), and its lead candidate RAP-219 is a negative allosteric modulator that selectively targets TARP gamma-8, a protein expressed only in specific brain regions such as the hippocampus where focal seizures originate. That selectivity is meant to differentiate RAP-219 from broad AMPA antagonists like Eisai's perampanel, which act throughout the brain and carry tolerability limits. The company went public in June 2024 at $17 per share, raising roughly $174 million, and is advancing RAP-219 across focal epilepsy, bipolar mania, and peripheral neuropathic pain.

The investment picture is a classic pre-commercial biotech profile: no product revenue, ongoing net losses, and a valuation driven by clinical milestones rather than fundamentals. In April 2026 Rapport reported Phase 2a follow-up data in drug-resistant focal onset seizures showing roughly a 90% median reduction in clinical seizures with sustained effect, which supported an accelerated move into Phase 3. The company reported about $476.8 million in cash and short-term investments as of March 31, 2026, funding operations into the second half of 2029, so the near-term risk is scientific and regulatory rather than financial. Yahoo Finance lists about $436 million of cash against about $10 million of debt as of June 30, 2026.

Since then the company has started its Phase 3 FOCUS 1 and FOCUS 2 trials in focal onset seizures, and topline results from the Phase 2 bipolar mania trial were targeted for October 2026. The Q2 2026 net loss widened to about $56.6 million (EPS of -$1.19 versus -$0.99 expected) as Phase 3 spending ramped, after a Q1 that included about $20 million of collaboration revenue. The shares fell sharply in late September amid a broad biotech selloff and closed near $27.52 on October 16, 2026, down about 32% over one month and 2.1% year to date but up about 10.7% over one year, for a market cap near $1.3 billion. Analyst coverage keeps widening: William Blair, Guggenheim ($65 target) and UBS ($71 target) all initiated with positive ratings between July and October 2026.

As a clinical-stage biotech, Rapport has no approved products and no product revenue, so the equity is highly sensitive to trial outcomes. Phase 2a results, while encouraging, come from small patient numbers and do not guarantee success in larger, longer Phase 3 trials, where efficacy or safety signals can weaken. The company depends heavily on a single molecule, RAP-219, meaning a failure in one indication can cast doubt across the pipeline. Even with runway into 2H 2029, eventual commercialization or additional trials may require dilutive financing. Regulatory delays, competition from entrenched anti-seizure therapies, and typical biotech volatility all add meaningful uncertainty. The bipolar mania read-out expected in October 2026 is a near-term binary event, and the roughly 32% decline in the month before it shows how quickly sentiment can swing even without company-specific news.

15 analysts publish price targets on RAPP, averaging $62.71 against a $27.57 price as of October 2026, or +127.5%. The published targets run from $50.00 to $80.00, a moderate spread, and the ratings split 16 buy, 0 hold, 0 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RAPP forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Rapport Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. RAP-219 lead program momentum. Positive Phase 2a follow-up data in focal onset seizures (about 90% median reduction in clinical seizures in weeks 9-12) prompted Rapport to accelerate into Phase 3, and the FOCUS 1 and FOCUS 2 focal onset seizure trials are now under way. The most optimistic published target, $80.00, assumes this works close to its best case.

The case against. As a clinical-stage biotech, Rapport has no approved products and no product revenue, so the equity is highly sensitive to trial outcomes. The most pessimistic target, $50.00, is roughly what RAPP is worth if this bites instead.

Read the full bull and bear case on RAPP, including what would have to change to break either one. Walnut is not an investment adviser.

No. Rapport Therapeutics, Inc. (RAPP) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Rapport Therapeutics, Inc.'s investor relations page or your broker.

• Market cap: ~$1.3B (stock ~$27.52 on October 16, 2026)
• Cash (June 30, 2026): ~$436M, debt ~$10M
• Q2 2026 net loss: ~$56.6M (EPS ~-$1.19 vs ~-$0.99 expected)
• Net loss (TTM): ~$137M
• Revenue (TTM): ~$20M, all collaboration revenue booked in Q1 2026
• Cash runway: Into 2H 2029 (company guidance)
• Price-to-book: ~3.1x

Rapport is pre-commercial, so traditional valuation multiples do not apply and the market prices it on pipeline probability and cash runway. A roughly $1.3 billion market cap against about $436 million of cash implies investors still assign substantial value to RAP-219, though less than the roughly $1.8 billion valuation earlier in 2026. Analysts' mean target was about $63 across 15 analysts, more than double the share price, a gap that will be tested by the October 2026 bipolar read-out.

Other names that sit close to RAPP: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RAPP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RAPP sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RAPP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

RAPP is a single-asset neuroscience bet: strong early RAP-219 data and a deep cash cushion (about $436 million as of mid-2026), but the outcome hinges on a bipolar mania read-out expected in October 2026 and Phase 3 epilepsy trials that are years from resolving.

Whether RAPP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RAPP a buy or a sell?, and where the stock could go from here in the RAPP stock forecast.

For income investors, whether RAPP pays a dividend and how the payout looks is covered in does RAPP pay a dividend? And to weigh RAPP against a peer, read the full side-by-side comparisons: RAPP vs UCB and RAPP vs PRAX.